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SUMMARY
A randomised, double-blind, parallel, placebo-controlled,
12-week study was carried out to evaluate the efﬁcacy
and safety of 20-mg tadalaﬁl taken ‘as needed’ in a popu-
lation of men with erectile dysfunction (ED) from Egypt
and Turkey. One hundred and thirty-two patients were
randomised in this study. Tadalaﬁl was superior to pla-
cebo on all three co-primary efﬁcacy end points. The
mean change from baseline for the erectile function
domain of the International Index of Erectile Function
was 9.3   0.8 for the tadalaﬁl group and 2.3   1.6 for
the placebo group. Tadalaﬁl-treated patients reported a
signiﬁcantly greater improvement in the mean percentage
of successful penetrations (tadalaﬁl: 34.5   4.1; placebo:
)4.6   8.1) and successful intercourse attempts (tadala-
ﬁl: 52.2   3.8; placebo: 16.8   7.8) than placebo-trea-
ted patients as measured by the Sexual Encounter Proﬁle.
Tadalaﬁl was generally well tolerated with 82% of
adverse events being mild in severity. Tadalaﬁl 20-mg
taken ‘as needed’ signiﬁcantly improved the erectile func-
tion in Egyptian and Turkish men with ED.
Keywords: Tadalaﬁl; erectile dysfunction; randomised
controlled trial
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INTRODUCTION
The effects of erectile dysfunction (ED), deﬁned as the con-
sistent inability to achieve or maintain an erection sufﬁcient
for satisfactory sexual performance (1) can be devastating
and include decreased overall quality of life (2,3).
Erectile dysfunction is a condition that will affect one in
ten men over the age of 16 years at some time in their lives
and becomes more prevalent as men get older (4). The
Massachusetts Male Aging study found that 52% of men
between the ages of 40 and 70 had some degree of ED with
the incidence rate of complete impotence tripling from 5%
to 15% between men in the same age group (5). Similar
ﬁndings were observed in studies conducted in South Aus-
tralia, Finland, France and England (6). Contributing fac-
tors that may cause ED include vascular insufﬁciency,
interruption of neural pathways (7), diabetes mellitus, hor-
monal derangement, psychogenic factors and side effects of
concomitant pharmacotherapy.
Treatment of ED aims to gain a sustained improvement
in erectile function. Several pharmacotherapies have been
used to achieve this goal. The results with injectable treat-
ments were promising for many patients but because of
their invasive nature most men prefer less invasive agents
(8). Thus, the current climate in sexual medicine has
revealed an increased readiness to expand the indications of
oral vasoactive pharmacotherapy for the treatment of ED
(9). Out of these, it was the selective phosphodiesterase
(PDE) inhibitors that gained widespread interest for treating
ED (10). Eleven families of PDE isoenzymes are well recog-
nised and of these PDE type 5 (PDE5) was found to be the
isoenzyme with the greatest pharmacological relevance for
erectile function.(11). From this aspect PDE5 inhibitors
started to gain high demand over the invasive means in ED
treatment as they stimulate natural erectile responses by acti-
vation of biochemical mechanisms, producing the physiolo-
gical relaxation of erectile tissue (12). Tadalaﬁl (Cialis
 ;
Lilly ICOS LLC Bothell, WA, USA) is one of the most
recent PDE5 inhibitors introduced into the market. It
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extended period of responsiveness (up to 36 h) due to a
plasma half-life of 17.5 h and the lack of pharmacokinetic
interaction with food or beverage (10).
Tadalaﬁl has been approved for the treatment of ED in
Egypt and Turkey as well as in the USA, European coun-
tries, and in other countries around the world. This study
was undertaken to evaluate the efﬁcacy and safety of 20-mg
tadalaﬁl taken ‘as needed’ in improving erectile function
over 12 weeks, in a population of men with ED from Egypt
and Turkey.
MATERIALS AND METHODS
Study Design
This randomised, double-blind, parallel, placebo-controlled
study was conducted at seven sites in two countries. The
ethical review board for each investigative site approved the
protocol and informed consent document. The study was
conducted in accordance with the protocol and ethical prin-
ciples stated in the Declaration of Helsinki 2002 and
applicable local laws of each country.
The study objectives were to evaluate the efﬁcacy and
safety of ‘as needed’ dosing of 20 mg tadalaﬁl administered
for 12 weeks to men with ED. ‘As needed’ dosing in this
study refers to the administration of tadalaﬁl prior to the
potential for sexual activity, but at a maximum frequency of
one dose per day. Thirty doses, to be available ‘as needed’,
were dispensed to patients at visits.
The study consisted of two periods. The ﬁrst period was
the screening period of approximately 4 weeks’ duration
starting from time when the eligible patients signed the
informed consent document till the end of the fourth week
at visit 2. Screened patients were stratiﬁed at randomisation
by the International Index of Erectile Function (IIEF) Erec-
tile Function domain scores in the following category: mild
ED ¼ a score higher or equal to 17, moderate ED ¼ 11–
16, and severe ED ¼ 1–10. Patients were randomly
assigned to treatment groups in a 1:3 (placebo:20 mg tad-
alaﬁl) fashion. This was followed by a treatment period that
lasted approximately 12 weeks.
The International Index of Erectile Function and the Sex-
ual Encounter Proﬁle (SEP) diary were administered
through the treatment period. Global Assessment Questions
(GAQ) were asked at the end of treatment period or at the
early discontinuation visit.
Patient Population
Study participants were male patients at least 18 years of
age who anticipated having the same female sexual part-
ner during the study and had symptoms of ED (deﬁned
as the consistent inability to achieve or maintain an erec-
tion sufﬁcient for satisfactory sexual performance) with
any kind of severity and any aetiological reasons for at
least 3 months. Major exclusion criteria were: ED caused
by premature ejaculation or untreated endocrine disease;
failure to achieve erection after pelvic surgery including
radical prostatectomy (except bilateral nerve-sparing) or
patients receiving nitrates, anti-androgens or chemother-
apy; signiﬁcant penile deformity or penile implant; clinic-
ally signiﬁcant renal or hepatic insufﬁciency; poorly
controlled diabetes (haemoglobin A1c113%); a recent
history of stroke or spinal cord trauma; unstable cardio-
vascular diseases (e.g. unstable angina, recent myocardial
infarction or coronary intervention, history of sudden car-
diac arrest despite medical or device therapy, evidence of
congestive heart failure, new signiﬁcant conduction defect
or uncontrolled hypertension). Patients with prior ineffec-
tive treatment with sildenaﬁl citrate, in the opinion of
the investigator, could have been excluded from the
study. Concomitant use of other therapies for ED was
not allowed during the study. Although the study was
originally planned to be performed in three countries
with 189 patients, 139 patients from Egypt and Turkey
participated in the study. The study remained sufﬁciently
(190%) powered for all co-primary end point analyses.
Efﬁcacy Measures
The ﬁrst co-primary efﬁcacy measure was the IIEF Erectile
Function domain, deﬁned as the sum of questions 1–5 and
15 of the IIEF. The IIEF was administered at the end of
the treatment-free run-in period, and at the end of 4, 8 and
12 weeks of treatment. Further co-primary efﬁcacy measures
were the mean per patient percent of ‘yes’ responses to SEP
question 2 [SEP2: Were you able to insert your penis into
your partner’s vagina? (yes/no)] and SEP3 [Did your erec-
tion last long enough for you to have successful intercourse?
(yes/no)].
Secondary efﬁcacy measures of the study include: IIEF
Intercourse Satisfaction and Overall Satisfaction Domain
scores, IIEF questions 3 and 4, mean per patient percent of
‘yes’ responses to SEP4 (Were you satisﬁed with the hardness
of your erection?) and SEP5 (Were you satisﬁed overall with
this sexual experience?) and responses to two GAQ questions
(GAQ1-Has the treatment you have been taking during this
study improved your erections? GAQ2-If yes, has the treat-
ment improved your ability to engage in sexual activity?).
Safety
Safety was assessed by evaluating the incidence of treatment-
emergent adverse events and any changes in laboratory
results or vital signs. At the screening and last study visit a
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performed. A 12-lead ECG was also performed at the ﬁrst
visit. Study personnel recorded concomitant medication use,
blood pressure and pulse at every visit. The date of onset or
resolution of any adverse event was recorded at each study
visit. Treatment-emergent adverse events (events that ﬁrst
occurred or worsened after baseline) were summarised by
the Medical Dictionary for Regulatory Activities (MedDRA)
version 5.0, and severity and possible relationship to study
drug were noted.
Statistical Analysis
The co-primary efﬁcacy variables were mean change from
baseline to end point in the IIEF EF domain score and
mean changes from baseline to the post-baseline period in
the mean per patient percent of ‘yes’ responses to SEP2
and SEP3.
The null hypothesis was that tadalaﬁl and placebo did
not differ on each of the three co-primary efﬁcacy end
points. To reject the null hypothesis a signiﬁcance of 0.05
was required (two-tailed). The study had 90% power to
detect a signiﬁcant treatment effect in each of the three
co-primary efﬁcacy variables at the 0.05 alpha level.
The efﬁcacy analyses were conducted on an intent-to-
treat basis. Efﬁcacy analyses included all patients who had a
baseline measurement and at least one post-baseline meas-
urement. The scores on the IIEF domains and questions
were analysed using the last observation carried forward
convention. For each SEP question the baseline and post-
baseline scores were analysed as the mean per patient per-
cent of ‘yes’ responses (number of yes responses relative to
the number of sexual encounters during the run-in and
treatment periods respectively).
The efﬁcacy variables were analysed using analysis of
covariance (ANCOVA) models, including terms for baseline
efﬁcacy value, treatment group, pooled site and baseline-
by-treatment group interaction (if p 0 0.10). Logistic
regression was performed to evaluate the GAQ using the
same terms as in the ANCOVA model except that the base-
line IIEF EF domain value was used in the model as a
covariate. Only patients who responded to the GAQ were
included in the model. An additional analysis of the per-
centage of patients who returned to normal erectile func-
tion (as deﬁned by an IIEF Erectile Function Domain
score of  26) by baseline severity after treatment was
performed.
Safety analyses included all randomised patients. The
incidence of treatment-emergent adverse events between
treatment groups was compared. The statistical analyses in
this study were conducted using the SAS statistical pack-
age version 8.2 for windows (SAS Institute, Cary, NC,
USA).
RESULTS
Patient Demographics and Patient Disposition
Of the 139 patients who entered the study, 132 were rand-
omised to treatment (31 to placebo, 101 to tadalaﬁl). Sixty
patients were randomised in Turkey and 72 in Egypt. Most
of the baseline characteristics including ED severity and ED
aetiology were balanced between the two treatment groups
(Table 1). A larger proportion in the placebo group
(22.6%) had hypertension than in the tadalaﬁl group
(9.9%) while a larger proportion in the tadalaﬁl group
(75.2%) had an ED duration  1 year than in the placebo
group (64.5%). All patients in this study were Caucasian.
Eighty-one per cent (25/31) of placebo-treated patients
and 83% (81/101) of tadalaﬁl-treated patients completed
the study. Of the 23 discontinuations, three tadalaﬁl and
zero placebo patients discontinued due to an adverse event.
Other reasons for discontinuation including patient decis-
ion, lost to follow-up, protocol violation and death are sum-
marised in Figure 1.
There were no statistically signiﬁcant differences between
the two treatment groups with respect to the mean number of
days on therapy (placebo 105.1 days and tadalaﬁl 98.7 days),
the mean of total doses taken during the study (29.5 for pla-
cebo and 39.2 for tadalaﬁl) or the mean number of doses
taken per week (2.1 for placebo and 2.8 for tadalaﬁl).
Efﬁcacy Results
Tadalaﬁl was superior to placebo on all three primary efﬁc-
acy end points with p 0 0.001 (Table 2). The mean
change (  standard errors) from baseline on the IIEF EF
domain was 2.3   1.6 for the placebo and 9.3   0.8 for
the tadalaﬁl group. Tadalaﬁl-treated patients reported a sig-
niﬁcantly greater improvement in the mean per patient per-
cent of yes on SEP 2 (successful penetration) (tadalaﬁl:
34.5   4.1%; placebo: )4.6   8.1%) and SEP 3 (success-
ful intercourse) (tadalaﬁl: 52.2   3.8%; placebo:
16.8   7.8%) than placebo-treated patients.
In addition, the mean change from baseline on the IIEF
EF domain score was greater among the tadalaﬁl-treated
patients than among the placebo-treated patients across all
ED severity groups (Figure 2).
Tadalaﬁl signiﬁcantly improved erectile function and was
superior to placebo on all secondary efﬁcacy variables. Tad-
alaﬁl treatment signiﬁcantly improved IIEF Intercourse Sat-
isfaction and Overall Satisfaction domain scores from
baseline and resulted in higher end point scores on these
two IIEF domains when compared with placebo (Table 2).
Responses to IIEF questions 4 and 5 assessing penetration
ability and erection maintenance indicated that the improve-
ment from baseline with tadalaﬁl was signiﬁcantly greater
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patients had a signiﬁcantly greater change from baseline
compared with placebo-treated patients for SEP4 (satisfac-
tion with erection hardness) and SEP5 (overall satisfaction
with sexual experience) (p 0 0.001 for both, Table 2). Sig-
niﬁcantly more tadalaﬁl-treated patients reported an
improvement in their erections (‘yes’ response to GAQ1,
p 0 0.001) and in the ability to engage in sexual activity
(‘yes’ response to GAQ2, p 0 0.001) compared with pla-
cebo-treated patients (Table 2).
Across all ED severity categories, tadalaﬁl was associated
with a higher proportion of patients achieving normal erec-
tile function at end point as measured by the IIEF EF
domain (score of  26) (13). Overall, 56.3% of patients
reported erectile function within the normal range at end
point in the tadalaﬁl group and 28.6% in the placebo group
(Figure 3).
Safety
The most commonly reported treatment-emergent adverse
events ( 5%) were headache (tadalaﬁl 16.8 %, placebo 9.7
%), back pain (tadalaﬁl 6.9%, placebo 0%) and dyspepsia
(2 % tadalaﬁl, 6.5% placebo). Most (82%) of the adverse
events reported by tadalaﬁl-treated patients were mild in
severity and generally well tolerated. Three patients (3%) in
the tadalaﬁl group discontinued due to adverse events that
were considered by the investigators as possibly related to
study drug (Figure 1). One patient (55 years old) in the
tadalaﬁl group died of cardiac arrest. This patient had mul-
tiple cardiovascular risk factors, including obesity, smoking,
diabetes mellitus and hypertension. Because there was no
medical follow-up related to the event, the investigator
could not exclude a relationship to study drug or protocol
procedures. No other serious adverse events or clinically sig-
niﬁcant ﬁndings related to vital signs and laboratory analytes
were reported.
DISCUSSION
Tadalaﬁl at the 20 mg dose taken ‘as needed’ signiﬁcantly
improved erectile function in men with mild, moderate
or severe ED compared with placebo in this study popu-
lation from Egypt and Turkey. This is the ﬁrst multi-
Table 1 Patients demographics and
baseline clinical characteristics Characteristic Placebo (n ¼ 31) Tadalaﬁl (n ¼ 101)
Mean age, years (range) 51.7 (27.8–66.1) 48.7 (26.6–67.7)
Mean weight   SD (kg) 83.97   14.91 80.73   11.68
Mean height   SD (cm) 170.84   5.53 172.79   7.79
Aetiology, n (%)
Psychogenic 2 (6.5) 11 (10.9)
Organic 9 (29.0) 31 (30.7)
Mixed 20 (64.5) 59 (58.4)
Erectile dysfunction severity
measured by IIEF EF score, n (%)
Mild (17–30) 11 (35.5) 35 (34.7)
Moderate (11–16) 12 (38.7) 38 (37.6)
Severe (1–10) 8 (25.8) 28 (27.7)
ED duration, n (%)
 3t o0 6 months 4 (12.9) 15 (14.9)
 6 months to 1 year 7 (22.6) 10 (9.9)
 1 year 20 (64.5) 76 (75.2)
Smokers 10 (32.3) 36 (35.6)
Consumes alcohol 2 (6.5) 7 (6.9)
Mean weekly consumed alcohol units* 0.13 0.12
Pre-existing conditions, n (%)
Patients with  1 condition 18 (58.1) 41 (40.6)
Diabetes mellitus 8 (25.8) 21 (20.8)
Hypertension 7 (22.6) 10 (9.9)
Benign prostatic hyperplasia 2 (6.5) 4 (4.0)
Hypercholesterolaemia 1 (3.2) 3 (3.0)
Hyperlipidaemia 2 (6.5) 1 (1.0)
Urinary tract infection 2 (6.5) 1 (1.0)
Patients were included based on a history of erectile dysfunction. Subsequent assessment of erectile
function by IIEF at baseline revealed that two (2%) tadalaﬁl-treated patients had an EF domain score
in the normal range (26–30). *Mean alcohol unit for randomised patients. Conditions that are more
frequent than 5% in any of the treatment group are shown in this table.
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men with ED in this region of the world. Patients taking
tadalaﬁl reported signiﬁcant improvement (p 0 0.001) on
each of the co-primary efﬁcacy end points compared with
placebo (Figures 3 and Table 2). As an example, an
increase of 52% from baseline in the mean per patient
percent of ‘yes’ responses to SEP3 (successful intercourse)
and a mean increase of 9.3 from baseline in IIEF EF
domain score was reported by men with ED treated with
tadalaﬁl. These ﬁndings are consistent with previous stud-
ies assessing the efﬁcacy of tadalaﬁl in the treatment of
ED relative to placebo (14–19).
A signiﬁcant number of tadalaﬁl-treated patients across
all ED severity categories (41–84%) achieved a normal IIEF
EF domain score (between 26 and 30) at end point (13).
This is consistent with the ﬁndings of recent tadalaﬁl studies
evaluating the efﬁcacy of tadalaﬁl treatment in European
populations (19,20). The placebo responses in this study
across all severity groups are somewhat higher than in the
integrated studies (15), especially the rate for the severe
group. It might be associated with the random variation
due to the sparseness of data in the placebo group. Overall,
in this study of men with ED from Egypt and Turkey,
more than half of the patients (56%) had IIEF EF domain
Patient screened (N = 139)
Excluded (n = 7)
Protocol entry criteria not met (n = 4)
Personal conflict or other patient decision (n = 2)
Protocol violation (n = 1)
Patient randomized (N = 132)
31 Patients randomized to placebo and 
included in analysis
101 patients randomized to Tadalafil 
20 mg and included in analysis
Discontinued (n = 6)
Protocol violation 
(n = 2)
Lost to follow-up
(n = 4)
Discontinued (n = 17)
Protocol violation 
(n = 4)
Lost to follow-up
(n = 4)
Patient conflict or 
other decision (n = 5)
Adverse event (n = 3)
Death (n = 1)
Completed (n = 25) Completed (n = 84)
Figure 1 Study ﬂow diagram
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treatment.
Tadalaﬁl also showed similar efﬁcacy results on all secon-
dary efﬁcacy measurements (Table 2). Tadalaﬁl improved
patients’ erections, erection hardness, penetration ability,
maintenance of erection, intercourse satisfaction and overall
satisfaction. At the end of the study, 76% of patients repor-
ted improvement in the ability to engage in sexual activity.
These results together with the primary efﬁcacy ﬁndings of
the study provide further support for the efﬁcacy of tadalaﬁl
in the treatment of ED. Our results conﬁrm those reported
previously across various geographies (20–23) and extend
the results to men from Egypt and Turkey.
In prior studies with PDE 5 inhibitors, headache and
dyspepsia were the common adverse events (16,24). Head-
ache, back pain and dyspepsia were the most common
adverse events reported in our study during the 12 week
treatment period and the majority of these events were mild
in severity. Likewise, Carson et al. found in his integrated
Table 2 Primary and secondary efﬁcacy results
Placebo (n ¼ 31) Tadalaﬁl 20 mg (n ¼ 101)
p-value Baseline End point Change (mean   SE) Baseline End point Change (mean   SE)
Primary end points
IIEF EF domain 14.5 16.8 2.3   1.6 14.5 23.8 9.3   0.8 00.001
SEP2 (successful penetration)
(mean per patient % yes)
55.6 51.0 )4.6   8.1 44.4 78.9 34.5   4.1 00.001
SEP3 (successful intercourse)
(mean per patient % yes)
17.9 34.7 16.8   7.8 14.0 66.1 52.2   3.8 00.001
Secondary end points
IIEF questions
IIEF Q3. Penetration ability 2.7 2.9 0.2   0.3 2.6 4.1 1.5   0.2 00.001
IIEF Q4. Maintenance ability 2.0 2.8 0.8   0.3 1.9 3.9 2.0   0.2 00.001
IIEF domains
Intercourse satisfaction 7.1 9.4 2.3   0.7 6.4 11.2 4.8   0.3 0.001
Overall satisfaction 4.6 5.7 1.1   0.6 4.0 7.6 3.6   0.3 00.001
Patient SEP questions (mean per patient % yes)
SEP4 (satisﬁed with hardness) 8.7 30.3 21.7   6.8 8.6 61.4 52.8   3.8 00.001
SEP5 (overall satisfaction) 8.7 29.2 20.5   6.8 8.1 57.3 49.1   3.9 00.001
GAQ (% of patients with ‘yes’ response)
GAQ1. Improved erections 41.9 81.2 00.001
GAQ2. Improved sexual activity 41.9 76.2 00.001
IIEF, International Index of Erectile Function; SEP, Sexual Encounter Proﬁle; GAQ, Global Assessment Question.
0.3
7.5
0.2
14.8
8.2
6.3
0
2
4
6
8
10
12
14
16
Mild
M
e
a
n
 
c
h
a
n
g
e
 
I
I
E
F
 
E
F
 
d
o
m
a
i
n
 
s
c
o
r
e
Moderate Severe
Placebo
Tadalafil
n = 9    n = 32 n = 11   n = 37 n = 8    n = 27
Figure 2 Mean change from baseline in International Index of
Erectile Function (IIEF) erectile function domain score, by
baseline erectile dysfunction severity
28.6
18.2
33.3
37.5
56.3
43.2
84.4
40.7
0
10
20
30
40
50
60
70
80
90
100
Mild Moderate Severe Overall
Placebo
Tadalafil
n = 9 n = 32 n = 11 n = 37 n = 8 n = 27 n = 28 n = 96
%
Figure 3 Percentage of patients attaining normal International
Index of Erectile Function (IIEF) erectile function (EF) domain
score ( 26 at end point) by baseline erectile dysfunction severity
n ¼ patients with normal IIEF EF domain score (EF ¼ 26) at end
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severity (15). Tadalaﬁl was generally well tolerated in this
population, with 3% of patients receiving tadalaﬁl discon-
tinuing due to adverse events.
One limitation of the study may arise from the selection
of the patient population. A recent sex survey conducted
with Turkish men aged between 40 and 65 years (25)
showed that the admission rate to a medical professional for
ED is low (7%). Therefore, patients enrolled in this study
may represent a highly motivated sample of men with ED
seeking medical advice rather than the overall male ED
population.
CONCLUSIONS
In this randomised, double-blind, placebo-controlled study
conducted in Egypt and Turkey, 20 mg ‘as needed’ tad-
alaﬁl without restrictions on food and beverage intake sig-
niﬁcantly improved patients’ erectile function. In this
study, 56% of patients treated with tadalaﬁl achieved nor-
mal IIEF EF domain scores ( 26) and tadalaﬁl was well
tolerated.
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